Transplantation of hematopoietic progenitors in myelofibrosis.

The objective of this work is to generate recommendations on the management of allogeneic stem cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic review of articles published between 1999 and 2015 (January) was used as a source of scientific evidence. The recommendations were produced through a Delphi process involving a panel of 23 experts appointed by the European LeukemiaNet and the European Blood and Marrow Transplantation Group. Key questions included patient selection, donor selection, pre-transplant management, conditioning regimen, post-transplant management, prevention, and management of post-transplant relapse. Patients with intermediate-2 or high-risk disease and age < 70 years should be considered candidates for allo-SCT. Patients with intermediate-risk 1 disease and age < 65 years should be considered candidates if they have refractory transfusion-dependent anemia, or a peripheral blood (PB) blast percentage > 2%, or adverse cytogenetics. Splenectomy before transplantation must be decided on a case-by-case basis. Patients with intermediate-2 or high-risk disease who lack a human leukocyte antigen (HLA)-matched sibling or unrelated donor should be enrolled in a protocol that uses HLA non-identical donors. PB was considered the most appropriate source of hematopoietic stem cells for transplants from HLA-matched unrelated donors and siblings. The optimal intensity of the conditioning regimen has yet to be defined. Strategies such as discontinuation of immunosuppressive drugs, infusion of donor lymphocytes, or both were considered adequate to prevent clinical relapse. In conclusion, we provide consensus-based recommendations aimed at optimizing allo-SCT in PMF. Unmet clinical needs were highlighted.

El objetivo de este trabajo es generar recomendaciones sobre el manejo del trasplante alogénico de células madre (alo-SCT) en la mielofibrosis primaria (MFP). Se utilizó una revisión sistemática integral de artículos publicados entre 1999 y 2015 (enero) como fuente de evidencia científica. Las recomendaciones se produjeron mediante un proceso Delphi en el que participó un panel de 23 expertos designados por la European LeukemiaNet y el European Blood and Marrow Transplantation Group. Las preguntas clave incluyeron la selección de pacientes, la selección de donantes, el manejo previo al trasplante, el régimen de acondicionamiento, el manejo posterior al trasplante, la prevención y el manejo de la recaída después del trasplante. Los pacientes con enfermedad de riesgo intermedio 2 o alto y edad < 70 años deben ser considerados candidatos para alo-SCT. Los pacientes con enfermedad de riesgo intermedio 1 y edad < 65 años deben ser considerados candidatos si presentan anemia refractaria dependiente de transfusiones, o un porcentaje de blastos en sangre periférica > 2%, o citogenética adversa. La esplenectomía previa al trasplante debe decidirse caso por caso. Los pacientes con enfermedad de riesgo intermedio 2 o alto que carecen de un hermano compatible con el antígeno leucocitario humano (HLA) o de un donante no emparentado deben inscribirse en un protocolo que utilice donantes no idénticos de HLA. PB se consideró la fuente más apropiada de células madre hematopoyéticas para trasplantes de hermanos y donantes no emparentados compatibles con HLA. La intensidad óptima del régimen de acondicionamiento aún debe definirse. Se consideraron adecuadas estrategias como la suspensión de los fármacos inmunosupresores, la infusión de linfocitos del donante o ambas para evitar la recaída clínica. En conclusión, proporcionamos recomendaciones basadas en consenso destinadas a optimizar el alo-SCT en MFP. Se destacaron las necesidades clínicas insatisfechas.

Essential thrombocythaemia.

Essential thrombocythemia (ET) is a chronic Philadelphia-negative myeloproliferative neoplasm that has its main involvement in the megakaryopoietic lineage, generating sustained thrombocytosis in peripheral blood and an increase in the number of mature megakaryocytes in the bone marrow. In addition to marked thrombocytosis, it is characterized by increased thrombotic or hemorrhagic risk and the presence of constitutional symptoms. Patients with ET have a low but known risk of disease progression to myelofibrosis and/or acute leukemia. The diagnosis is made based on the 2016 WHO criteria. At present, available treatments for patients with ET are mainly aimed at minimizing the risk of thrombosis and/or bleeding.

La trombocitemia esencial (TE) es una neoplasia mieloproliferativa crónica Filadelfia negativa que tiene su principal involucro en la línea megacariopoyética, generando trombocitosis sostenida en la sangre periférica y un incremento en el número de megacariocitos maduros en médula ósea. Además de una marcada trombocitosis, se caracteriza por un mayor riesgo trombótico o hemorrágico y la presencia de síntomas constitucionales. Los pacientes con TE tienen un riesgo bajo, pero conocido, de evolución de la enfermedad a mielofibrosis y/o leucemia aguda. El diagnóstico se realiza con base en los criterios de la Organización Mundial de la Salud del 2016. Los tratamientos actualmente disponibles para los pacientes con TE están dirigidos principalmente a minimizar el riesgo de trombosis y/o hemorragia.

Pregnancy in myeloproliferative neoplasms.

Myeloproliferative neoplasms (MPN) are associated with a significant risk of thrombosis and the hypercoagulable environment of pregnancy increases this risk. The most frequent gestational complications consist of spontaneous abortion, thrombosis, bleeding, and hypertensive disease of pregnancy. Treatment depends on thrombotic risk, gestational trimester, and myeloproliferative neoplasm.

Las neoplasias mieloproliferativas (NMP) están asociadas a un riesgo notable de trombosis y el entorno de hipercoagulabilidad propio del embarazo aumenta este riesgo. Las complicaciones gestacionales más frecuentes consisten en: aborto espontáneo, trombosis, sangrado y enfermedad hipertensiva del embarazo. El tratamiento depende del riesgo trombótico, trimestre gestacional y neoplasia mieloproliferativa.

Polycythemia vera.

Polycythemia vera (PV) is mainly characterized by erythrocytosis, thrombotic and hemorrhagic predisposition, a variety of symptoms, and cumulative risks of fibrotic progression and/or leukemic evolution over time. The diagnosis is made based on the 2016 WHO criteria. The treatment of PV focuses on rapidly reducing the erythrocyte mass, either by means of phlebotomies or with cytoreductive treatment, and the reduction of thrombotic risk by correcting cardiovascular risk factors and the use of platelet antiaggregants.

La policitemia vera (PV) se caracteriza principalmente por eritrocitosis, predisposición trombótica y hemorrágica, una variedad de síntomas y riesgos acumulativos de progresión fibrótica y/o evolución leucémica a lo largo del tiempo. El diagnóstico se realiza con base en los criterios de la Organización Mundial de la Salud del 2016. El tratamiento de la PV se centra en reducir rápidamente la masa eritrocitaria, ya sea por medio de flebotomías o con tratamiento citorreductor, y la disminución del riesgo trombótico mediante la corrección de factores de riesgo cardiovascular y el uso de antiagregantes plaquetarios.

Risks in invasive procedures.

Patients with myeloproliferative neoplasms have an increased risk of thrombosis and bleeding. This risk must be identified, as well as individualizing the therapeutic strategy before invasive procedures; adequate cytoreduction reduces the risk of complications.

Los pacientes con neoplasias mieloproliferativas tienen un riesgo incrementado de trombosis y sangrado. Se debe identificar dicho riesgo, así como individualizar la estrategia terapéutica previo a los procedimientos invasivos; una adecuada citorreducción disminuye el riesgo de complicaciones.

Symptom control.

In addition to symptoms secondary to splenomegaly, microvascular abnormalities, and thrombohemorrhagic complications, patients with MPN may experience a significant symptom burden attributed to an increase in circulating inflammatory cytokines. These symptoms can be severe and limit quality of life. Therefore, in addition to the prevention of complications, one of the objectives of the treatment of MPN is the control of symptoms.

Además de la sintomatología secundaria a la esplenomegalia, a las alteraciones microvasculares y a las complicaciones trombohemorrágicas, los pacientes con neoplasias mieloproliferativas (NMP) pueden experimentar una importante carga sintomática atribuida a un aumento de citocinas inflamatorias circulantes. Estos síntomas pueden ser severos y limitar la calidad de vida. Por ello, además de la prevención de las complicaciones, uno de los objetivos del tratamiento de las NMP es el control de los síntomas.

Thrombotic events.

Major thrombotic complications in myeloproliferative neoplasms (MPNs) represent an important clinical problem due to their high morbidity, the complexity of their management, and their associated mortality. The appearance of a thrombosis implies a high thrombotic risk stratification of the MPN and determines the initiation or optimization of cytoreductive treatment and the use of antiplatelet or anticoagulant therapy as secondary prophylaxis. The incidence of thrombosis at the time of diagnosis is higher than during the course of the disease, being located in the arterial territory in 60-70% of cases. Once thrombosis has occurred, up to 20-33% of patients experience thrombotic recurrence in the same initial vascular territory.

Las complicaciones trombóticas mayores en las neoplasias mieloproliferativas (NMP) representan un importante problema clínico debido a su elevada morbilidad, la complejidad de su manejo y su mortalidad asociada. La aparición de una trombosis comporta una estratificación de alto riesgo trombótico de la NMP y determina el inicio o la optimización del tratamiento citorreductor y el uso de terapia antiplaquetaria o anticoagulante como profilaxis secundaria. La incidencia de trombosis en el momento del diagnóstico es mayor que durante la evolución de la enfermedad, localizándose en territorio arterial en el 60-70% casos. Una vez se ha producido una trombosis, hasta el 20-33% de los pacientes sufre una recurrencia trombótica en el mismo territorio vascular inicial.

First inter-institutional consensus on Chronic Myeloproliferative Neoplasms.

The objective of the consensus is to make available to the professionals of the different public health institutions in our country, who are in charge of these diseases, the most relevant and up-to-date information about their diagnosis and treatment in clinical practice. With this inter-institutional consensus we hope to contribute to improving the quality of care for patients with chronic myeloproliferative neoplasms throughout the Mexican Republic, to unify criteria in both diagnosis and treatment of the different myeloproliferative diseases.

OBJETIVO: El objetivo del consenso es poner a disposición de los profesionales de las diferentes instituciones de salud pública en nuestro país, quienes se encuentran a cargo de estas enfermedades, la información más relevante y actualizada acerca de su diagnóstico y tratamiento en la práctica clínica. Con este consenso interinstitucional esperamos contribuir a mejorar la calidad de la atención de los pacientes con neoplasias mieloproliferativas crónicas a todo lo ancho y largo de la República Mexicana, con el fin de unificar criterios tanto en diagnóstico como en tratamiento de las diferentes enfermedades mieloproliferativas.

Myelofibrosis: diagnosis and treatment.

Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines. In recent years, important progress has been made in the knowledge of the molecular biology and the prognostic assessment of MF. Conventional treatment has limited impact on the patients' survival; it includes a wait-and-see approach for asymptomatic patients, erythropoiesis-stimulating agents, androgens, or immunomodulatory agents for anemia, cytoreductive drugs such as hydroxyurea for the splenomegaly and constitutional symptoms, and splenectomy or radiotherapy in selected patients. The discovery of the Janus kinase (JAK) 2 mutation triggered the development of molecular targeted therapy of MF. The JAK inhibitors are effective in both JAK2-positive and JAK2-negative MF; one of them, ruxolitinib, is the current best available therapy for MF splenomegaly and constitutional symptoms. Although ruxolitinib has changed the therapeutic scenario of MF, there is no clear indication of a disease-modifying effect. Allogeneic stem cell transplantation remains the only curative therapy of MF, but due to its associated morbidity and mortality, it is usually restricted to eligible high- and intermediate-2-risk MF patients. To improve current therapeutic results, the combination of JAK inhibitors with other agents is currently being tested, and newer drugs are being investigated.

La mielofibrosis (MF) es una neoplasia mieloproliferativa negativa para BCR-ABL1 caracterizada por mieloproliferación clonal, señalización de cinasa desregulada y liberación de citocinas anormales. En los últimos años se han realizado importantes avances en el conocimiento de la biología molecular y la valoración pronóstica de la MF. El tratamiento convencional tiene un impacto limitado en la supervivencia de los pacientes; incluye un enfoque de espera para pacientes asintomáticos, agentes estimulantes de la eritropoyesis, andrógenos o agentes inmunomoduladores para la anemia, fármacos citorreductores como la hidroxiurea para la esplenomegalia y los síntomas constitucionales, y esplenectomía o radioterapia en pacientes seleccionados. El descubrimiento de la mutación Janus cinasa (JAK) 2 desencadenó el desarrollo de la terapia dirigida molecular de la MF. Los inhibidores de JAK son efectivos tanto en MF con JAK2 positivo como con JAK2 negativo; uno de ellos, el ruxolitinib, es la mejor terapia disponible actualmente para la esplenomegalia y los síntomas constitucionales de la MF. Sin embargo, aunque el ruxolitinib ha cambiado el escenario terapéutico de la MF, no hay indicios claros de un efecto modificador de la enfermedad. El alotrasplante de células madre sigue siendo la única terapia curativa de la MF, pero debido a su morbilidad y mortalidad asociadas, generalmente se restringe a pacientes elegibles con MF de riesgo alto e intermedio 2. Para mejorar los resultados terapéuticos actuales, actualmente se está probando la combinación de inhibidores de JAK con otros agentes y se están investigando fármacos más nuevos.

The use of Proteinase K to access genitalia morphology, vouchering and DNA extraction in minute wasps.

Genitalia are rich source of characters in insect taxonomy. Usually, they are examined after dissection and cleaning with potassium hydroxide (KOH), procedure that may damage both genital morphological structures and intracellular molecular contents. Enzymatic procedure with Proteinase K has been used to clean muscle off the genitalia while extract DNA, but its damage to the genital structures has not been evaluated. Herein, we qualitatively compare the use of KOH and Proteinase K to prepare genital structures in minute insects (Hymenoptera: Bethylidae). We show that Proteinase K is better to preserve the genital structure and provides quality DNA.

Oral Contraceptive Use and Prevalence of Self-Reported Glaucoma or Ocular Hypertension in the United States.

PURPOSE: To investigate the association between oral contraceptive (OC) use and glaucoma prevalence in the United States. DESIGN: Cross-sectional study. PARTICIPANTS: A total of 3406 female participants, aged 40 years or older, from the 2005 to 2008 National Health and Nutrition Examination Survey, who reported a presence or absence of glaucoma or ocular hypertension completed both the vision and the reproductive health questionnaires and underwent eye examinations. METHODS: Multivariate regression analysis was used to assess the correlation between OC use and self-reported glaucoma or ocular hypertension (n = 231 cases), controlling for potential confounders, including age, ethnicity, systemic comorbidities such as hypertension and stroke, ocular diseases such as cataract and diabetic retinopathy, and reproductive health factors, including age at menopause, age at menarche, history of hormone replacement therapy, and gynecological surgical history. MAIN OUTCOME MEASURES: The outcome variable was self-reported glaucoma or ocular hypertension. RESULTS: After adjusting for confounders, those with ≥3 years of OC use had greater odds (odds ratio, 1.94; 95% confidence interval, 1.22-3.07) of self-reported glaucoma or ocular hypertension. Other factors associated with higher glaucoma or ocular hypertension prevalence included older age, African American race, and later age at menarche. CONCLUSIONS: Oral contraceptive use may be associated with increased risk of self-reported glaucoma or ocular hypertension.

Correlation between the ganglion cell complex and structural measures of the optic disc and retinal nerve fiber layer in glaucoma.

To correlate the ganglion cell complex (GCC) parameters with structural measures of the optic nerve head (ONH) and retinal nerve fiber layer (RNFL) as evaluated by Fourier-Domain optic coherence tomography (OCT). This retrospective study included patients with glaucoma, ocular hypertensive patients and glaucoma suspects who had previously undergone OCT examination with the RTVue-100. The parameters of GCC (average, superior, inferior, focal loss volume [FLV], global loss volume [GLV]) were correlated with the values of the ONH (cup volume, cup area, horizontal cup-to-disk ratio, vertical cup-to-disk ratio, and rim area) and RNFL (average, superior, and inferior) using Pearson's correlation coefficient. The sample included 74 eyes of 37 patients. All correlations between GCC parameters and RNFL were strong (r > 0.60). The correlation between GCC parameters and ONH were good for most parameters, except that for FLV and cup volume (r = 0.13), GLV and cup volume (r = 0.09), and GLV and cup area (r = 0.21). The GCC parameters can be used as structural measures of the glaucomatous optic neuropathy.

Correlation between the ganglion cell complex and functional measures in glaucoma patients and suspects.

The purpose of the study was to correlate the Fourier-domain OCT ganglion cell complex (GCC) parameters with automated perimetry (AP) functional measures of the optic nerve. This retrospective study included patients who had previously undergone examination with the RTVue-100 OCT and AP, SITA strategy. The parameters of GCC (average, superior, inferior, S-I [superior inferior difference], S-I SD [standard deviation of S-I], GLV [global loss volume] and FLV [focal loss volume]) were correlated with the mean deviation (MD) and pattern standard deviation (PSD) values of AP using linear and logarithmic regression analysis. All correlations between GCC and automated perimetry parameters were strong (r > 0.60), except that for SI and MD (r = -0.05); SI and PSD (r = 0.09); SI-DS and MD (r = -0.06); and SI-SD and PSD (r = 0.08). In summary, GCC derived structural measures showed good correlation with functional parameters from AP.

A Tale's blade: Understanding evolutionary features of oviposition behavior based on Tettigoniidae (Insecta, Orthoptera, Ensifera) ovipositor morphology.

A remarkable characteristic of katydids (Orthoptera, Tettigoniidae) is the elongated ovipositor, which is associated with oviposition behavior. The high degree of complexity of both sclerites and muscles arrangement of the ovipositor, is only similar to the ovipositor of Hymenoptera. Here we describe the morphology of the ovipositor within Tettigoniidae, and add descriptions of known oviposition behavior. Fifteen skeletal structures can be recognized, of these, three pairs of muscles are new while nine pairs were already described in the literature. The new muscles are ap2vf, anterior projection of second valvifer; bcov, blade complex of the ovipositor; and dbl, dorsal blade. The morphology of the ovipositor blade complex (bcov), the shape of the first valvifer (1vf), posterior intervalvular sclerite (piv), tergite IX (T9), anterior projection of the second valvifer (ap2vf), and the second valvifer (2vf), and their related muscles affect oviposition in Tettigoniidae. This contribution helps to understand katydid's oviposition behavior. Additionally, the new descriptions help in the search for new characters in Tettigoniidae.

[Financialization, accumulation, and shareholding changes in companies and corporate groups in the Brazilian health sector]. / Financeirização, acumulação e mudanças patrimoniais em empresas e grupos econômicos do setor saúde no Brasil.

This study aims to analyze the shareholding dimension of changes in companies and corporate groups in the Brazilian health sector from 2008 to 2017. The idea was to understand the strategies of accumulation in a context of financialization, defined as a systemic pattern of wealth in contemporary capitalism. The shareholding changes were submitted to descriptive and exploratory analysis based on different sources. We studied 58 companies from the subsectors of health plans, pharmacies, hospitals, diagnostics, pharmaceutical industry, and social organizations. Data were collected on the legal structure, ownership, and control, equity operations, and economic and patient care activities. Despite the heterogeneity of the companies and their strategies, the results point to an increase in the presence of domestic and international investors, changes in internal organization, capital, financing, and diversification of activities. The companies that stood out were actively pursuing capitalization via foreign investments, purchase and share of assets and shares, and mergers and acquisitions, accelerating the process of expansion, accumulation, and shareholding and financial appreciation. The result is an increase in capital flows and growing integration of economic and patient care structures in the Brazilian health sector with financial circuits, thereby linking peripheral intermediate companies to an expanded process of accumulation under financial dominance. The findings corroborate striking aspects of corporate dynamics in financialization that increasingly influence health systems in Brazil and the world.

O objetivo deste trabalho é analisar a dimensão patrimonial de mudanças em empresas e grupos econômicos do setor saúde no Brasil entre 2008 e 2017. Busca-se compreender as estratégias de acumulação em um contexto de financeirização, compreendida como padrão sistêmico da riqueza no capitalismo contemporâneo. As mudanças patrimoniais foram analisadas de forma descritiva e exploratória a partir de diferentes fontes. Foram estudadas 58 empresas dos subsetores de planos de saúde, farmácias, hospitais, diagnóstico, indústria farmacêutica e organizações sociais. Foram coletados dados sobre forma jurídica, propriedade e controle; operações patrimoniais; atividades econômicas e assistenciais. A despeito da heterogeneidade das empresas e suas estratégias, os resultados apontam o aumento da presença de investidores nacionais e internacionais, mudanças na organização interna, na estrutura do capital, no financiamento e diversificação de atividades. As que mais se destacam buscaram ativamente a capitalização a partir de investimentos externos, compra e venda de ativos e ações, fusões e aquisições aceleram o processo de expansão, acumulação e valorização patrimonial-financeira. O resultado é o aumento do fluxo de capitais e a crescente integração das estruturas econômicas e assistenciais do setor saúde brasileiro aos circuitos financeiros, tornando as empresas intermediárias periféricas articuladas a um processo ampliado de acumulação sob dominância financeira. Os achados convergem com aspectos marcantes da dinâmica das corporações na financeirização, que influenciam cada vez mais os sistemas de saúde no Brasil e do mundo.

El objetivo de este trabajo es analizar la dimensión patrimonial de cambios en empresas y grupos económicos del sector salud en Brasil entre 2008 y 2017. Se busca comprender las estrategias de acumulación en un contexto de financiarización, comprendida como un patrón sistémico de la riqueza en el capitalismo contemporáneo. Los cambios patrimoniales fueron analizados de forma descriptiva y exploratoria a partir de diferentes fuentes. Se estudiaron 58 empresas de los subsectores de planes de salud, farmacias, hospitales, diagnóstico, industria farmacéutica y organizaciones sociales. Se recogieron datos sobre forma jurídica, propriedad y control; operaciones patrimoniales; actividades económicas y asistenciales. A pesar de la heterogeneidad de las empresas y sus estrategias, los resultados apuntan el aumento de la presencia de inversores nacionales e internacionales, cambios en la organización interna, estructura del capital, financiación y diversificación de actividades. Las que más se destacan buscaron activamente la capitalización a partir de inversiones externas, compra y venta de activos y acciones, fusiones y adquisiciones aceleraron el proceso de expansión, acumulación y valorización patrimonial-financiera. El resultado es el aumento del flujo de capitales y la creciente integración de las estructuras económicas y asistenciales del sector salud brasileño en los circuitos financieros, haciendo que las empresas intermediarias periféricas se coordinaran con un proceso ampliado de acumulación, auspiciado por el dominio financiero. Los resultados convergen con aspectos marcantes de la dinámica de las corporaciones en la financiarización, que influencian cada vez más los sistemas de salud en Brasil y en el mundo.

Persistently high hepatitis C rates in haemodialysis patients in Brazil [a systematic review and meta-analysis].

We conducted a systematic review and meta-analysis of studies assessing HCV infection rates in haemodialysis patients in Brazil (Prospero CRD #42021275068). We included studies on patients under haemodialysis, comprising both convenience samples and exhaustive information from selected services. Patients underwent HCV serological testing with or without confirmation by HCV RNA PCR. Exclusion criteria were the following: absence of primary empirical information and studies without information on their respective settings, study year, accurate infection rates, or full specification of diagnostic tests. Studies with samples ≤ 30 and serial assessments with repeated information were also excluded. Reference databases included PubMed, LILACS, Scopus, and Web of Science for the period 1989-2019. A systematic review was carried out, followed by two independent meta-analyses: (i) studies with data on HCV prevalence and (ii) studies with a confirmatory PCR (i.e., active infection), respectively. A comprehensive set of different methods and procedures were used: forest plots and respective statistics, polynomial regression, meta-regression, subgroup influence, quality assessment, and trim-and-fill analysis. 29 studies and 11,290 individuals were assessed. The average time patients were in haemodialysis varied from 23.5 to 56.3 months. Prevalence of HCV infection was highly heterogeneous, with a pronounced decrease from 1992 to 2001, followed by a plateau and a slight decrease in recent years. The summary measure for HCV prevalence was 34% (95% CI 26-43%) for studies implemented before 2001. For studies implemented after 2001, the corresponding summary measure was 11% (95% CI 8-15%). Estimates for prevalence of active HCV infection were also highly heterogeneous. There was a marked decline from 1996 to 2001, followed by a plateau and a slight increase after 2010. The summary measure for active HCV infection was 19% (95% CI 15-25%) in studies carried out before 2001. For studies implemented after 2001, the corresponding summary measure was 9% (95% CI 6-13%). Heterogeneity was pervasive, but different analyses helped to identify its underlying sources. Besides the year each study was conducted, the findings differed markedly between geographic regions and were heavily influenced by the size of the studies and publication biases. Our systematic review and meta-analysis documented a substantial decline in HCV prevalence among Brazilian haemodialysis patients from 1992 to 2015. CKD should be targeted with specific interventions to prevent HCV infection, and if prevention fails, prompt diagnosis and treatment. Although the goal of HCV elimination by 2030 in Brazil remains elusive, it is necessary to adopt measures to achieve micro-elimination and to launch initiatives towards targeted interventions to curb the spread of HCV in people with CKD, among other high-risk groups. This is of particular concern in the context of a protracted COVID-19 pandemic and a major economic and political crisis.

Morphology of sting apparatus of Chrysidoidea (Hymenoptera, Aculeata).

The main synapomorphy for Aculeata is the sting apparatus, which allows the female to envenom potential prey or hosts. The sting is the modified ovipositor which is not used for laying eggs anymore. Here, we explore the morphology of the sting apparatus within the families of Chrysidoidea. 27 skeletal structures were recognized, including three (dp1vf, dorsal projection of first valvifer; ppa, projection of posterior area of the second valvifer; vl9, ventral lap of tergite 9) that have not been observed previously, and 13 pairs of muscles, including four (superior dorsal T9-2vf (M5); inferior dorsal T9-2vf (M6); postero-lateral T9-2vf/mbr (M9); anterolateral 2vf/bl-2vv/fu (M11)) that have not been observed previously. Very conserved morphological patterns were observed; character support in the sting apparatus was found at the subfamily level, and within three families at the genus level. In addition, we describe the variation within the sting apparatus structures and musculature, propose evolutionary hypotheses about the function and evolution of the structures, and summarize phylogenetic conclusions for Chrysidoidea.

Rating of perceived capacity: a proposal to predict adequate levels of physical activity in visually impaired individuals.

BACKGROUND: There are several instruments that are generally used to analyze levels of physical activity (PA) in people with visual impairment. However, few instruments are validated for this population. The purpose of this study was to compare the subjective and objective variables of PA and to propose the use of the Rating of Perceived Capacity (RPC) to evaluate the level of moderate to vigorous physical activity (MVPA) per day in this population. METHODS: Thirty-seven individuals with visual impairment participated in the study (19 blind without light perception and 18 low-vision). For the subjective physical activity evaluation, it was used the International Physical Activity Questionnaire Short Form (IPAQ-SF) and for the objective evaluation, it was used the ActiGraph GT3X+. RESULTS: Among the three analyzed (PA) intensities: moderate physical activity (MPA), vigorous physical activity (VPA) and MVPA, in VPA and MVPA was observed differences between the two methods (P=0.002 and P=0.011 respectively). Furthermore, the concordance between subjective and objective MVPA was not observed (ICC=0.239; P=0.176), and a greater variability of differences in MVPA between the two methods was observed by the Bland Altman scatter plot. However, positive correlation was found between the RPC and MVPA (P=0.470; P=0.003). In addition, in the Receiver Operating Characteristic (ROC) curve analysis, it was verified that values greater than 8 points in the RPC showed a predictive capacity for sufficient levels of objective MVPA (AUC=0.809, sensitivity =66.7, specificity =90.9, P≤0.001). CONCLUSIONS: We concluded that the MVPA per day obtained by IPAQ-SF did not show agreement for the objective MVPA in visually impaired individuals. On the other hand, RPC presented itself as an alternative, practical and accessible tool to predict adequate levels of MVPA per day in this population.

SUBJECTIVE SLEEP NEED AND DAYTIME SLEEPINESS IN ADOLESCENTS.

OBJECTIVE: To analyze the contribution of subjective sleep need for daytime sleepiness in adolescents, and to compare questions about sleep, age and body mass index between adolescents who considered to sleep enough and those who reported the need for more sleep. METHODS: This is a descriptive, epidemiological and cross-sectional study. Data collection was performed in August 2016, with 773 adolescents aged 14-19 years old, from Paranaguá, Paraná, Southern Brazil. The analysis included the following variables: time in bed, half-sleep phase, sleep need, social jetlag, daytime sleepiness, body mass index and physical activity. RESULTS: The prevalence of adolescents with subjective need for sleep was 73.0%, with an average need of 1.7 extra hours of sleep. These adolescents woke up earlier (p<0.001) and slept less on school days (p<0.001). The need for more sleep was associated with higher daytime sleepiness scores (rho=0.480; p<0.001) and with later half-sleep phase (rho=0.200; p<0.001). No correlation was identified between the sleep need and time in bed (rho=-0.044; p=0.225). The subjective sleep need was the variable with the greatest explanatory power for daytime sleepiness (24.8%; p<0.001). In addition, the less adolescents practiced physical activity, the higher their daytime sleepiness scores (rho=-0.117; p<0.001). CONCLUSIONS: The subjective sleep need has an important role in explaining daytime sleepiness among adolescents. Adolescents who needed to sleep more reported waking up early and experienced sleep deprivation during class days; they also woke up later on the weekends and experienced more daytime sleepiness, compared to those who believed they had enough sleep.

Factors associated with excessive daytime sleepiness among Brazilian adolescents.

This study aimed to verify the prevalence and factors associated with excessive daytime sleepiness (EDS) among adolescents. In all, 1.132 people participated. They were aged between 14 and 19 years, of both sexes and they came from a city in southern Brazil. Many socio-demographic variables were collected (sex, age group, socioeconomic status, period of study, year of school and work), also variables related to their health (level of physical activity, alcohol intake, smoking, misuse of medicines, stress control, duration of sleep, sedentary behavior and self-rated health) and EDS, through the Pediatric Daytime Sleepiness Scale (PDSS). The prevalence of EDS in general sample was 54.2% and average score in PDSS was 16.0 (5.7). Comparing results between both sexes, female sex presents the higher prevalence of EDS (64.3%) and greatest average PDSS score 17.5 (5.4) compared to male sex (35.7%) with 14.5 (5.6%) score (p < .001). In analysis of the prevalence ratio, using 15 as an EDS cut-off point, prevalence was 35% higher in the female sex (PR = 1.35 CI 95% 1.08-1.69, p = .010). In addition, adolescents which had lower self-rated health (PR = 1.24 CI 95% 1.01-1.52, p = .038), low stress control (PR = 1.28 CI 95% 1.05-1.57, p = .014) and short sleep duration (PR = 1.30 CI 95% 1.02-1.65, p = .029), presented higher prevalence of EDS. High prevalence of EDS was identified, being more common in young women. Adequate sleep, greater stress control and better health perception should be promoted among Brazilian adolescents.